IKT
Inhibikase Therapeutics, Inc.
Overview
Inhibikase Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $242.9M market cap.
IKT missed consensus EPS by 0.1% in Q1 FY2026, reported May 12, 2026.
11 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q2 FY2024Earnings2024-08-158 Q&A exchanges
- Q1 FY2024Earnings2024-05-176 Q&A exchanges
- Q4 FY2023Earnings2024-03-283 Q&A exchanges
- Q3 FY2023Earnings2023-11-156 Q&A exchanges
- Q2 FY2023Earnings2023-08-154 Q&A exchanges
- Q1 FY2023Earnings2023-05-164 Q&A exchanges
- Q4 FY2022Earnings2023-04-031 Q&A exchange
- Q3 FY2022Earnings2022-11-151 Q&A exchange
- Q2 FY2022Earnings2022-08-157 Q&A exchanges
- Q1 FY2022Earnings2022-05-17
- Q4 FY2021Earnings2022-04-01
History
Earnings history
- Q1 FY20262026-05-12EPS$-0.10 vs $-0.09-5.7%Rev$0 vs ——EODHD
- Q4 FY20252026-03-26EPS$-0.09 vs $-0.12+23.9%Rev$0 vs ——EODHD
- Q3 FY20252025-11-12EPS$-0.13 vs $-0.13-1.9%Rev$0 vs ——EODHD
- Q2 FY20252025-08-13EPS$-0.11 vs $-0.08-37.5%Rev$0 vs ——EODHD
- Q1 FY20252025-05-13EPS$-0.15 vs $-0.09-66.7%Rev$0 vs ——EODHD
- Q4 FY20242025-03-24EPS$-0.17 vs $-0.09-100.0%Rev$26.3K vs ——EODHD
- Q3 FY20242024-11-13EPS$-0.65 vs $-0.48-35.4%Rev$0 vs ——EODHD
- Q2 FY20242024-08-13EPS$-0.66 vs $-0.67+1.5%Rev$0 vs ——EODHD
- Q1 FY20242024-05-14EPS$-0.73 vs $-0.79+7.6%Rev$0 vs ——EODHD
- Q4 FY20232024-03-26EPS$-0.64 vs $-0.85+24.7%Rev$1 vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.86 vs $-1.12+23.2%Rev$79.6K vs ——EODHD
- Q2 FY20232023-08-13EPS$-1.11 vs $-0.92-20.6%Rev$116.4K vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.16 vs $-0.14-14.3%Rev$64.5K vs ——EODHD
- Q4 FY20222023-03-30EPS$-0.18 vs $-0.19+5.3%Rev$123.4K vs ——EODHD
- Q3 FY20222022-11-13EPS$-0.18 vs $-0.180.0%Rev$7.3K vs ——EODHD
- Q2 FY20222022-08-11EPS$-0.18 vs $-0.19+5.3%Rev$6.6K vs ——EODHD
- Q1 FY20222022-05-15EPS$-0.18 vs $-0.17-5.9%Rev$46.0K vs ——EODHD
- Q4 FY20212022-03-30EPS$-0.20 vs $-0.17-17.6%Rev$1.9K vs ——EODHD
- Q3 FY20212021-11-14EPS$-0.18 vs $-0.14-28.6%Rev$328.5K vs ——EODHD
- Q2 FY20212021-08-15EPS$-0.22 vs $-0.38+42.1%Rev$1.4M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-12 | $-0.10 | $-0.09 | -5.7% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-0.09 | $-0.12 | +23.9% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.13 | $-0.13 | -1.9% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.11 | $-0.08 | -37.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $-0.15 | $-0.09 | -66.7% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-24 | $-0.17 | $-0.09 | -100.0% | $26.3K | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-0.65 | $-0.48 | -35.4% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.66 | $-0.67 | +1.5% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-0.73 | $-0.79 | +7.6% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-26 | $-0.64 | $-0.85 | +24.7% | $1 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.86 | $-1.12 | +23.2% | $79.6K | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-1.11 | $-0.92 | -20.6% | $116.4K | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.16 | $-0.14 | -14.3% | $64.5K | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.18 | $-0.19 | +5.3% | $123.4K | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.18 | $-0.18 | 0.0% | $7.3K | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.18 | $-0.19 | +5.3% | $6.6K | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.18 | $-0.17 | -5.9% | $46.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.20 | $-0.17 | -17.6% | $1.9K | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-0.18 | $-0.14 | -28.6% | $328.5K | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.22 | $-0.38 | +42.1% | $1.4M | — | — | EODHD |
Source: EODHD. IKT reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks IKT's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 90% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2024 | $1.86 | $1.73 | +7.4% | -0.3% | -2.6% |
| Q4 FY2024 | $2.07 | $1.71 | +21.2% | -6.6% | -8.6% |
| Q3 FY2024 | $1.92 | $1.61 | +19.2% | -6.1% | -7.9% |
| Q2 FY2024 | $2.01 | $1.84 | +9.1% | -0.9% | -3.8% |
| Q1 FY2023 | $1.87 | $1.75 | +6.7% | -0.1% | +1.8% |
| Q4 FY2023 | $2.02 | $1.76 | +14.8% | -4.8% | -2.3% |
| Q3 FY2023 | $2.03 | $1.79 | +13.4% | -2.6% | -0.4% |
| Q2 FY2023 | $2.02 | $1.78 | +13.4% | +0.9% | -0.4% |
| Q1 FY2022 | $2.01 | $1.85 | +8.5% | -7.8% | -10.4% |
| Q4 FY2022 | $1.95 | $1.78 | +9.4% | -7.1% | -8.9% |
Guidance change history
Sample- Q1 FY2024Raised2024-04-15
- Q4 FY2024Raised2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Raised2023-10-15
- Q2 FY2023Raised2023-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Mark T IwickiCEO1 yr 4 mono recorded callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • guidance suspended Q1 FY2024
- David McIntyreCFO1 yr 2 mono recorded callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last guidance cut Q3 FY2024
- Christopher CabellPresident1 yr 4 mono recorded callsCurrentSample
PRESIDENT since 2025 • 1/2 beats (50%) • last call held guidance Q2 FY2024
- Milton H WernerCEO0 mo10 callsFormerSample
CEO since 2025 • 1/2 beats (50%) • guidance suspended Q3 FY2024
- Garth Lees-rolfeCFO0 mo3 callsFormerSample
CFO since 2025 • 1/2 beats (50%) • last guidance cut Q3 FY2024
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IKT.
$ curl https://api.spokenalpha.com/v1/companies/IKTFAQ
Frequently asked about IKT
Where can I find Inhibikase Therapeutics, Inc.'s (IKT) earnings call transcripts?
Spoken Alpha indexes IKT's earnings call transcripts at https://spokenalpha.com/companies/IKT. Each call links to attributed speakers and parsed analyst Q&A. Inhibikase Therapeutics, Inc.'s own investor relations page is at https://ir.linkedin.com/.
When was Inhibikase Therapeutics, Inc.'s most recent earnings call?
Inhibikase Therapeutics, Inc. (IKT) held its most recent earnings call on 2024-08-15, covering fiscal Q2 2024.
What sector is IKT in?
Inhibikase Therapeutics, Inc. (IKT) operates in the Healthcare sector (Biotechnology industry).